Le Lézard
Classified in: Health, Business
Subjects: ERN, CCA, ERP

Indivior Announces Q1 2024 Financial Results


SLOUGH, United Kingdom and RICHMOND, Va., April 25, 2024 /PRNewswire/ -- Indivior PLC (LSE/Nasdaq: INDV) today announced its financial results for the period ending March 31, 2024. The earnings release, investor presentation and webcast are available at www.indivior.com.

Indivior

There will be a live webcast presentation at 13:00 BST (8:00 am EST) hosted by Mark Crossley, CEO. The details are below.

Webcast link: https://edge.media-server.com/mmc/p/hktzzit4
Participants may access the presentation telephonically by registering with the following link: https://register.vevent.com/register/BI2351ee9819db40d1a28c31f75cece519

(Registrants will have an option to be called back directly immediately prior to the call or be provided a call-in # with a unique pin code following their registration) 

About Indivior

Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat substance use disorders (SUD) and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of SUD, including alcohol use disorder and cannabis use disorder. Headquartered in the United States in Richmond, VA, Indivior employs more than 1,000 individuals globally and its portfolio of products is available in 37 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior

Logo - https://mma.prnewswire.com/media/1814851/Indivior_Logo.jpg


These press releases may also interest you

at 22:34
Cynata Therapeutics Limited , a clinical-stage biotechnology company specialising in cell therapeutics, has successfully completed its Phase 1 clinical trial of CYP-006TK in diabetic foot ulcers (DFU). Key Highlights The trial met its primary...

at 21:44
BioArctic AB's (publ) partner Eisai today announced that the Federal Commission for the Protection Against Sanitary Risk (COFEPRIS) in Mexico has approved Leqembi (lecanemab) for the treatment of early Alzheimer's disease (AD)1.   Leqembi...

at 20:20
dBio has joined the American Heart Association Center for Health Technology & Innovation (the Center) Innovators' Network, an initiative focused on building and fostering health technology relationships to develop innovative and scalable...

at 20:05
The Asian Entrepreneurship Award (AEA) Steering Committee is pleased to announce that AEA2024, the 13th annual innovation award event for fast-growing Asian startups, was held on November 20th and 21st. Taking place in-person for the first time in...

at 18:40
Roswell Park CEO Candace S. Johnson, PhD, introduces center's first Physician in Chief, leaders in strategic areas Michael Wong, MD, PhD, FRPC, joins Roswell Park from MD Anderson...

at 18:31
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. announced today that the Federal Commission for the Protection Against Sanitary Risk (COFEPRIS) in Mexico has approved humanized anti-soluble aggregated amyloid-beta...



News published on and distributed by: